Dogwood Therapeutics, Inc. (DWTX) Stock Forecast & Price Target
Dogwood Therapeutics, Inc. · NASDAQ
$1.52+0.02 (+1.33%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Dogwood Therapeutics, Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 689% above the current $1.52. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Dogwood Therapeutics, Inc.
As of Jul, 1 of 1 firms rate DWTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DWTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.15 – $-0.14 · 3 analysts · -98% YoY
Next period, 3 analysts expect Dogwood Therapeutics, Inc. to earn $-0.14 a share (range $-0.15 – $-0.14), versus $-8.20 a year earlier. Full-year consensus is $-0.58, growing to $-0.65 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Dogwood Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DWTX.
#1
Sean Lee
HC Wainwright & Co. · Rank #191
Buy
$12.00+689.5% to target
Overall win rate
43%
+ Follow
DWTX stock forecast FAQ
What is DWTX's average 12-month price target?+
The 1 analysts with a live target average $12.00 for Dogwood Therapeutics, Inc. over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is DWTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover DWTX?+
1 analysts have an active rating on Dogwood Therapeutics, Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering DWTX?+
Among analysts who currently cover DWTX, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #191). Their current call is Buy with a $12.00 target.
What is Dogwood Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.15 – $-0.14) across 3 analysts. Full-year EPS is projected at $-0.58, rising to $-0.65 the following year.
How much revenue is Dogwood Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading DWTX lately?+
As of Jul, 1 of 1 firms rate DWTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DWTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
